Diamedica Therapeutics Inc Stock Price, News & Analysis

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, will participate in the 12th Annual Craig-Hallum Alpha Select Conference on November 16, 2021. Management is available for one-on-one meetings, and interested investors can contact their Craig-Hallum representative to schedule. DiaMedica’s lead candidate, DM199, is aimed at treating acute ischemic stroke and chronic kidney disease. The company has initiated the ReMEDy Phase 2/3 trial for acute ischemic stroke and is completing enrollment in the REDUX Phase 2 trial for chronic kidney disease.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced FDA approval to proceed with its Phase 2/3 ReMEDy2 trial for DM199, targeting acute ischemic stroke (AIS). The trial will now assess DM199's impact on stroke recovery and recurrence as independent primary endpoints. This decision is based on prior clinical data showing no recurrent strokes in DM199-treated patients versus a 13.3% rate in the placebo group. Stroke recurrence is significant, with 25% of U.S. strokes being recurrent, highlighting the urgent need for better treatments.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) will release its third quarter 2021 financial results post-market on November 10, 2021. A conference call is scheduled for November 11, 2021, at 7:00 AM CT to discuss the results and provide a business update. The call can be accessed via telephone or webcast, with a replay available until November 18, 2021. The company focuses on neurological disorders and kidney diseases, with its lead candidate, DM199, aimed at treating acute ischemic stroke and chronic kidney disease.

DiaMedica Therapeutics Inc. (NASDAQ: DMAC) announced that late-breaking data from its Phase 2 REDUX trial of DM199 for chronic kidney disease will be presented at the American Society of Nephrology's Kidney Week meeting. The presentation will include an update to interim data announced in June 2021. The session is set for November 4, 2021, highlighting ongoing research into DM199's effectiveness, a recombinant form of KLK1, which may address critical health issues including stroke and kidney disease.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced that its lead candidate DM199 received Fast Track Designation from the FDA for treating acute ischemic stroke (AIS). This designation aims to expedite the development and review process for drugs addressing serious conditions with unmet medical needs. CEO Rick Pauls emphasized the importance of this milestone, allowing for closer collaboration with the FDA. DM199, a recombinant form of tissue kallikrein-1, is under study for acute ischemic stroke and chronic kidney disease, representing a potential breakthrough after 25 years without significant new therapies.

DiaMedica Therapeutics (Nasdaq: DMAC) announced the completion of a $30 million private placement, selling 7.7 million shares at $3.92 each. This financing, yielding net proceeds of approximately $29.8 million, will bolster the company's balance sheet and support clinical trials for DM199, its lead program targeting acute ischemic stroke. Following this placement, DiaMedica's cash reserves will total around $51.1 million. The shares sold are unregistered under U.S. securities laws but will be registered for resale. DM199 is a synthetic form of KLK1, aimed at treating various serious conditions.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) has announced a definitive agreement for a $30 million private placement with ten accredited investors, priced at $3.92 per share, matching the closing price on September 24, 2021. The company plans to use the proceeds to support clinical development of DM199, including the ReMEDy2 trial, and for general corporate purposes. The placement is expected to close on September 28, 2021, pending customary conditions. DM199 is a recombinant form of KLK1, being studied for acute ischemic stroke and chronic kidney disease.

DiaMedica Therapeutics has initiated its ReMEDy2 Trial, a pivotal Phase 2/3 study of DM199 aimed at treating acute ischemic stroke (AIS). The trial will enroll 350 patients across 75 U.S. sites, focusing on a 24-hour treatment window. DM199 targets patients unable to use the traditional tPA treatment due to strict time constraints. The study will assess recovery and stroke recurrence rates, addressing a significant medical need for 700,000 U.S. stroke patients annually. This trial marks a potential breakthrough in stroke therapy, offering a new treatment modality in 25 years.

DiaMedica Therapeutics (NASDAQ: DMAC) will participate in three investor conferences from September 13 to September 23, 2021. The H.C. Wainwright 23rd Annual Global Investment Conference will take place from September 13-15, featuring one-on-one meetings and an on-demand presentation starting at 7:00 am ET. The Lake Street Capital Best Ideas Growth Conference is scheduled for September 14-15, followed by the Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit from September 20-23, both including one-on-one meetings. For more details, visit their website.